Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and ramiprilat

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with ramiprilat in 1 studies

Compound Research Comparison

Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Recent Studies (post-2010)
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Studies
(ramiprilat)		Trials
(ramiprilat)		Recent Studies (post-2010) (ramiprilat)
9,156187552173910

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Felsch, A; Schrör, K1

Other Studies

1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and ramiprilat

ArticleYear
Ramiprilat prevents PAF-induced myocellular and endothelial injury in a neutrophil-perfused heart preparation.
    Agents and actions. Supplements, 1992, Volume: 38 ( Pt 3)

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Creatine Kinase; Endothelium, Vascular; Guinea Pigs; Heart; Humans; In Vitro Techniques; Myocardial Contraction; Myocardium; Neutrophils; Perfusion; Peroxidase; Platelet Activating Factor; Ramipril; Superoxide Dismutase; Ventricular Function, Left

1992